A New York court has found enough evidence to allow the defamation lawsuit filed by Spanish pharmaceutical company Grifols against short seller Gotham City Research to proceed. This ruling was confirmed by Grifols in a statement on Friday.
The lawsuit stems from Gotham City's actions that allegedly caused a significant drop in Grifols' share price in January, following a report accusing the drugmaker of deceptive accounting. The court's decision means Grifols can continue its legal challenge against these claims.
This development is a step forward for Grifols in its efforts to defend its reputation and financial integrity against what it has described as 'unwarranted attacks'. The continuation of the lawsuit underscores the company's commitment to addressing the allegations through legal channels.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.